Cure8 research brief
This study tests a novel method to deliver healthy mitochondria to the gut lining and reports improved cellular energy, barrier function, and decreased oxidative stress in a mouse model of ulcerative colitis—suggesting a potential new direction for treatments that target epithelial energy failure.
Researchers in mitochondrial therapy and IBD, translational scientists, and clinicians following experimental regenerative therapies for ulcerative colitis.
This paper describes a laboratory-developed biomimetic coacervate “protocell” (HTP) that encapsulates isolated mitochondria for delivery to intestinal epithelial cells.
In mouse tests using dextran sulfate sodium (DSS) to model ulcerative colitis, rectal administration of HTP@Mito improved epithelial ATP levels, mitochondrial membrane potential, reduced oxidative stress, and appeared to restore epithelial barrier features and mucus secretion.
The authors report that HTP preserves mitochondrial function ex vivo longer than free mitochondria, enhances cellular uptake via lipid-raft-mediated endocytosis, and—by reducing oxidative stress—helps restore lysosomal and autophagic function and mitophagy.
They also report shifts in gut microbial groups (an increase in Lachnospiraceae and decrease in Escherichia-Shigella) in treated mice. This is an early-stage, preclinical laboratory study in mice and isolated mitochondria, not a clinical trial.
The paper establishes a delivery platform and presents physiological and microbiome findings in an animal model, which are hypothesis-generating rather than practice-changing.
Preclinical study with mouse DSS model and ex vivo mitochondria; results are promising but preliminary and not directly applicable to patient care yet.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This study describes a local rectal therapy that combines mesalamine with probiotic‑derived extracellular vesicles to promote mucosal healing and reduce inflammation in ulcerative colitis models, which could point toward...
The work links a missing bacterial metabolite (HDCA) to macrophage metabolism and reduced intestinal inflammation in experimental models, highlighting a potential microbiome-derived pathway that could be targeted for...
This preclinical study connects an herbal medicine to changes in gut microbiota, inflammation, and intestinal barrier function in a mouse model of ulcerative colitis — findings that could inform future research on new...
